RYTELO (imetelstat), FDA Approved for Treatment of Patients with Low- to Intermediate-1 Risk Myelodysplastic Syndromes (MDS) with Transfusion-dependent Anemia, Available at Biologics by McKesson
Biologics by McKesson was selected as a limited specialty pharmacy provider for RYTELO, a first-in-class telomerase inhibitor for certain patients with lower-risk myelodysplastic syndromes and transfusion-dependent anemia.